Shoji Fumihiro, Kozuma Yuka, Toyokawa Gouji, Yamazaki Koji, Takeo Sadanori
Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Fukuoka, Japan.
Ann Thorac Cardiovasc Surg. 2020 Oct 21;26(5):248-255. doi: 10.5761/atcs.oa.19-00315. Epub 2020 Feb 19.
Complete blood cell count (CBC)-derived inflammatory biomarkers are widely used as prognostic parameters for various malignancies, but the best predictive biomarker for early-stage non-small-cell lung cancer (NSCLC) is unclear. We retrospectively analyzed early-stage NSCLC patients to investigate predictive effects of preoperative CBC-derived inflammatory biomarkers.
We selected 311 consecutive patients with pathological stage IA NSCLC surgically resected from April 2006 to December 2012. Univariate and multivariate Cox proportional analyses of recurrence-free survival (RFS) were used to test the preoperative systemic immune inflammation index (SII), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR).
Preoperative high MLR levels were significantly associated with patient sex, smoking status, and postoperative recurrence (p <0.0001, p = 0.0307, and p = 0.0146, respectively), and preoperative high SII levels were significantly correlated with postoperative recurrence (p = 0.0458). Neither NLR nor PLR were associated with any related factors. Only preoperative MLR levels (p = 0.0269) were identified as an independent predictor of shorter RFS. The relative risk (RR) for preoperative high MLR level versus low level patients was 2.259 (95% confidence interval [CI]: 1.094-5.000). Five-year RFS rates in patients with preoperatively high MLR levels were significantly lower than in those with low MLR levels (82.21% vs. 92.05%, p = 0.0062). In subgroup analysis by tumor size and MLR level, the high MLR level subgroup with tumors >2 cm had significantly shorter RFS than other subgroups (p = 0.0289).
The preoperative MLR level is the optimal predictor of recurrence in patients with pathological stage IA NSCLC.
全血细胞计数(CBC)衍生的炎症生物标志物被广泛用作各种恶性肿瘤的预后参数,但早期非小细胞肺癌(NSCLC)的最佳预测生物标志物尚不清楚。我们回顾性分析了早期NSCLC患者,以研究术前CBC衍生的炎症生物标志物的预测作用。
我们选择了2006年4月至2012年12月期间手术切除的311例连续病理分期为IA期的NSCLC患者。采用无复发生存期(RFS)的单因素和多因素Cox比例分析来检测术前全身免疫炎症指数(SII)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和单核细胞与淋巴细胞比值(MLR)。
术前高MLR水平与患者性别、吸烟状况及术后复发显著相关(分别为p<0.0001、p = 0.0307和p = 0.0146),术前高SII水平与术后复发显著相关(p = 0.0458)。NLR和PLR均与任何相关因素无关。仅术前MLR水平(p = 0.0269)被确定为RFS较短的独立预测因子。术前高MLR水平患者与低水平患者的相对风险(RR)为2.259(95%置信区间[CI]:1.094 - 5.000)。术前高MLR水平患者的5年RFS率显著低于低MLR水平患者(82.21%对92.05%,p = 0.0062)。在按肿瘤大小和MLR水平进行的亚组分析中,肿瘤>2 cm的高MLR水平亚组的RFS明显短于其他亚组(p = 0.0289)。
术前MLR水平是病理分期为IA期NSCLC患者复发的最佳预测因子。